Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) have been given an average rating of "Moderate Buy" by the fourteen brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $182.79.

Several research analysts have issued reports on JAZZ shares. Needham & Company LLC reissued a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their price target for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Royal Bank of Canada decreased their price objective on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their target price for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Finally, Truist Financial upped their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th.

Jazz Pharmaceuticals Trading Down 8.8 %

NASDAQ JAZZ opened at $101.44 on Thursday. The firm's fifty day moving average price is $120.63 and its 200 day moving average price is $122.32. Jazz Pharmaceuticals has a 12 month low of $95.49 and a 12 month high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a market capitalization of $6.25 billion, a price-to-earnings ratio of 14.29, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business's revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the previous year, the business posted $2.68 EPS. On average, sell-side analysts expect that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,236 shares of company stock worth $3,956,190. 4.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Moloney Securities Asset Management LLC purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth about $464,000. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 13.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company's stock worth $4,420,000 after acquiring an additional 4,332 shares during the period. BTC Capital Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 9.4% in the fourth quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company's stock worth $6,115,000 after acquiring an additional 4,271 shares during the last quarter. Summit Trail Advisors LLC purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $539,000. Finally, Atria Investments Inc increased its position in Jazz Pharmaceuticals by 19.5% during the fourth quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock worth $336,000 after purchasing an additional 445 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.